SAMANTHA HALL: Open Payments
NPI 1235786674 · ROANOKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$709 in 24 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $360 · 2025 $709
Food & beverage: $709
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $141 |
| Xeris Pharmaceuticals, Inc. | 1 | $135 |
| Otsuka America Pharmaceutical, Inc. | 5 | $120 |
| Janssen Pharmaceuticals, Inc | 4 | $104 |
| Novo Nordisk Inc | 1 | $103 |
| ABBVIE INC. | 3 | $50 |
| Alkermes, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 1 | $15 |
Products named: INGREZZA, RECORLEV, INVEGA SUSTENNA, ABILIFY MAINTENA, VRAYLAR, SPRAVATO, ABILIFY ASIMTUFII, VIVITROL.
Industry payments across VA — which companies pay providers there.
